Abcellera Biologics, Inc. (ABCL)
NASDAQ:ABCL
Want to see ABCL full AI Analyst Report?
Total Valuation
AbCellera Biologics has a market cap or net worth of $1.60B. The enterprise value is $1.95B.
Market Cap$1.60B
Enterprise Value$1.95B
Share Statistics
AbCellera Biologics has 305,375,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding305,375,400
Owned by Insiders40.96%
Owned by Institutions19.86%
Financial Efficiency
AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -13.78%.
Return on Equity (ROE)-0.15
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-13.78%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee126.05K
Profits Per Employee-245.66K
Employee Count596
Asset Turnover0.06
Inventory Turnover4.55
Valuation Ratios
The current PE Ratio of AbCellera Biologics is ―. AbCellera Biologics’s PEG ratio is 0.64.
PE Ratio―
PS Ratio13.60
PB Ratio1.06
Price to Fair Value1.06
Price to FCF-5.87
Price to Operating Cash Flow-10.36
PEG Ratio0.64
Income Statement
In the last 12 months, AbCellera Biologics had revenue of 75.13M and earned -146.41M in profits. Earnings per share was -0.49.
Revenue75.13M
Gross Profit46.31M
Operating Income-217.10M
Pretax Income-177.59M
Net Income-146.41M
EBITDA-148.77M
Earnings Per Share (EPS)-0.49
Cash Flow
In the last 12 months, operating cash flow was -153.26M and capital expenditures -35.97M, giving a free cash flow of -189.23M billion.
Operating Cash Flow-153.26M
Free Cash Flow-189.23M
Free Cash Flow per Share-0.62
Dividends & Yields
AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change65.82%
50-Day Moving Average4.62
200-Day Moving Average4.24
Relative Strength Index (RSI)50.84
Average Volume (3m)8.60M
Important Dates
AbCellera Biologics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
AbCellera Biologics as a current ratio of 11.32, with Debt / Equity ratio of 14.94%
Current Ratio11.32
Quick Ratio11.23
Debt to Market Cap0.00
Net Debt to EBITDA-0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, AbCellera Biologics has paid -31.18M in taxes.
Income Tax-31.18M
Effective Tax Rate0.18
Enterprise Valuation
AbCellera Biologics EV to EBITDA ratio is -6.97, with an EV/FCF ratio of -5.95.
EV to Sales13.79
EV to EBITDA-6.97
EV to Free Cash Flow-5.95
EV to Operating Cash Flow-7.89
Balance Sheet
AbCellera Biologics has $504.73M in cash and marketable securities with $140.18M in debt, giving a net cash position of $364.55M billion.
Cash & Marketable Securities$504.73M
Total Debt$140.18M
Net Cash$364.55M
Net Cash Per Share$1.19
Tangible Book Value Per Share$2.95
Margins
Gross margin is 79.07%, with operating margin of -288.98%, and net profit margin of -194.88%.
Gross Margin79.07%
Operating Margin-288.98%
Pretax Margin-236.39%
Net Profit Margin-194.88%
EBITDA Margin-198.03%
EBIT Margin-236.39%
Analyst Forecast
The average price target for AbCellera Biologics is $9.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.40
Price Target Upside134.41% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast242.66%
EPS Growth Forecast15.53%